📊 IRTC Key Takeaways
Is iRhythm Holdings, Inc. (IRTC) a Good Investment?
iRhythm demonstrates strong 26% revenue growth with exceptional 70.9% gross margins, but operational execution is severely lacking with -$16.2M operating losses and -$33.1M negative free cash flow despite scale. For a medical device company generating $199.4M in revenue with such favorable unit economics, profitability should be achievable—indicating either unsustainable spending or structural inefficiencies that require substantial correction.
iRhythm shows strong fundamental momentum through 26.2% revenue growth, a high 70.6% gross margin, and positive operating and free cash flow, indicating that demand and unit economics remain solid. The balance sheet is liquid and leverage is modest, but persistent operating losses, negative net margins, and weak returns on equity show the business has not yet converted scale into durable profitability. The core story is improving growth quality with execution risk still present.
Why Buy iRhythm Holdings, Inc. Stock? IRTC Key Strengths
- Strong topline growth of 26.2% YoY in medical devices sector demonstrates market demand
- Exceptional gross margin of 70.9% indicates superior pricing power and cost structure
- Fortress balance sheet with $240.1M cash, low debt/equity of 0.22x, and 5.17x current ratio provides financial flexibility
- Strong top-line growth of 26.2% YoY suggests continued adoption and commercial traction
- High 70.6% gross margin supports attractive underlying economics and future operating leverage potential
- Healthy liquidity and positive free cash flow provide flexibility despite ongoing accounting losses
IRTC Stock Risks: iRhythm Holdings, Inc. Investment Risks
- Operating losses of -$16.2M despite high gross margins—suggests excessive OpEx relative to revenue generation capability
- Negative free cash flow of -$33.1M and negative operating cash flow of -$26.2M indicate company is burning cash despite rapid growth
- Unprofitable on both net income (-$13.9M) and EPS (-$0.43) basis—path to profitability remains undefined and execution is questionable
- Operating margin remains negative at -7.7%, showing the company has not yet achieved sustainable profitability
- ROE of -29.2% and a small equity base indicate weak shareholder returns and limited balance sheet cushion
- Negative interest coverage reflects earnings still insufficient to comfortably support financing costs from operations
Key Metrics to Watch
- Operating margin trajectory toward breakeven and positive profitability
- Operating cash flow inflection from negative to positive as revenue scales
- Operating expense growth rate relative to revenue growth rate—critical efficiency indicator
- Operating margin progression toward sustained profitability
- Free cash flow durability alongside continued revenue growth
iRhythm Holdings, Inc. (IRTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.17x current ratio provides a solid financial cushion.
IRTC Profit Margin, ROE & Profitability Analysis
IRTC vs Healthcare Sector: How iRhythm Holdings, Inc. Compares
How iRhythm Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is iRhythm Holdings, Inc. Stock Overvalued? IRTC Valuation Analysis 2026
Based on fundamental analysis, iRhythm Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
iRhythm Holdings, Inc. Balance Sheet: IRTC Debt, Cash & Liquidity
IRTC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: iRhythm Holdings, Inc.'s revenue has grown significantly by 131% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.04 indicates the company is currently unprofitable.
IRTC Revenue Growth, EPS Growth & YoY Performance
IRTC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $158.7M | -$13.9M | $-0.43 |
| Q3 2025 | $147.5M | -$5.2M | $-0.16 |
| Q2 2025 | $148.0M | -$14.2M | $-0.44 |
| Q1 2025 | $131.9M | -$30.7M | $-0.97 |
| Q3 2024 | $124.6M | -$18.5M | $-0.89 |
| Q2 2024 | $124.1M | -$18.5M | $-0.61 |
| Q1 2024 | $111.4M | -$39.1M | $-1.29 |
| Q3 2023 | $103.9M | -$18.5M | $-0.71 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
iRhythm Holdings, Inc. Dividends, Buybacks & Capital Allocation
IRTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for iRhythm Holdings, Inc. (CIK: 0001388658)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRTC
What is the AI rating for IRTC?
iRhythm Holdings, Inc. (IRTC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRTC's key strengths?
Claude: Strong topline growth of 26.2% YoY in medical devices sector demonstrates market demand. Exceptional gross margin of 70.9% indicates superior pricing power and cost structure. ChatGPT: Strong top-line growth of 26.2% YoY suggests continued adoption and commercial traction. High 70.6% gross margin supports attractive underlying economics and future operating leverage potential.
What are the risks of investing in IRTC?
Claude: Operating losses of -$16.2M despite high gross margins—suggests excessive OpEx relative to revenue generation capability. Negative free cash flow of -$33.1M and negative operating cash flow of -$26.2M indicate company is burning cash despite rapid growth. ChatGPT: Operating margin remains negative at -7.7%, showing the company has not yet achieved sustainable profitability. ROE of -29.2% and a small equity base indicate weak shareholder returns and limited balance sheet cushion.
What is IRTC's revenue and growth?
iRhythm Holdings, Inc. reported revenue of $199.4M.
Does IRTC pay dividends?
iRhythm Holdings, Inc. does not currently pay dividends.
Where can I find IRTC SEC filings?
Official SEC filings for iRhythm Holdings, Inc. (CIK: 0001388658) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRTC's EPS?
iRhythm Holdings, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRTC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, iRhythm Holdings, Inc. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRTC stock overvalued or undervalued?
Valuation metrics for IRTC: ROE of -8.6% (sector avg: 15%), net margin of -7.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRTC stock in 2026?
Our dual AI analysis gives iRhythm Holdings, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRTC's free cash flow?
iRhythm Holdings, Inc.'s operating cash flow is $-26.2M, with capital expenditures of $6.9M. FCF margin is -16.6%.
How does IRTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7.0% (avg: 12%), ROE -8.6% (avg: 15%), current ratio 5.17 (avg: 2).